期刊文献+

特发性肺纤维化患者血清肿瘤标志物水平与疾病严重程度关系分析 被引量:1

下载PDF
导出
摘要 目的分析特发性肺纤维化患者血清肿瘤标志物水平与疾病严重程度的关系。方法选取2017年6月-2018年8月建水县人民医院收治的肺部疾病患者60例,将患者分为特发性肺纤维化(16例)、结节病(11例)、结缔组织肺疾病(13例)和特发性肺纤维化合并肺癌(20例) 4组,对所有患者的血清肿瘤标志物进行分期,记录其血气分析结果。结果特发性肺纤维化患者在发病后其病症越严重CEA数值越高,特发性肺纤维化合并肺癌患者的数值最高,而结节病患者的数值最低;CA12-5、CA19-9数值与患者的病症严重程度呈正比,NSE数值与患者病症程度呈反比;相较于结节病来说,特发性肺纤维化患者CA15-3数值有明显升高,但这种指标与患者的病情严重程度并未呈现明显的比例关系,当患者发生严重肺部疾病后,CA15-3数值会明显增加,但具体增加量并不能直接反映患者的病症类型。结论患者发生特发性肺纤维化后,其体内CEA、CA12-5、CA19-9、CA15-3水平均明显升高,NSE数值与患者的病症状况呈反比。对患者进行辨证治疗和诊断时,可通过血清标志物的具体数值水平,对患者的病情严重程度进行分析,有助于了解患者病症发展状况,为后续治疗工作提供帮助和参考。
出处 《临床合理用药杂志》 2020年第16期164-165,共2页 Chinese Journal of Clinical Rational Drug Use
  • 相关文献

参考文献4

二级参考文献28

  • 1韩萍.特发性肺间质纤维化的中医治疗[J].青岛医药卫生,2004,36(2):115-115. 被引量:7
  • 2Raghu G, Collard H R, Egan J J, et ak An official ATS/ ERS/JRS/ALAT statement: idiopathic plmonary fibrosis: evidence-based guidelines for diagnosis and management [J]. Am J Respir Crit Care Med, 2011,183(6) :788-824.
  • 3American Thoracic S, European Respiratory S. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001 [J]. Am J Respir Crit Care Med, 2002,165(2):277-304.
  • 4Vancheri C, Failla M, Crimi N, et al. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology [J]. Eur Respir J, 2010,35(3):496-504.
  • 5Fahim A, Crooks M G, Wilmot R, et al. Serum carcinoembryonic antigen correlates with severity of idiopathic pulmonary fibrosis [J]. Respirology, 2012,17(8) : 1247-1252.
  • 6Haddad R, Massaro D. Idiopathic diffuse interstitial pulmonary fibrosis (fibrosing alveolitis), atypical epithelial proliferation and lung cancer [J]. Am J Med, 1968,45(2)211-219.
  • 7Fujita J, Dobashi N, Ohtsuki Y, et al. Elevation of anti- cytokeratin 19 antibody in sera of the patients with idiopathic pulmonary fibrosis and pulmonary fibrosis associated with collagen vascular disorders [J]. Lung, 1999,177(5)311-319.
  • 8Rusanov V, Kramer M R, Raviv Y, et al. The significance of elevated tumor markers among patients with idiopathic pulmonary fibrosis before and after lung transplantation [J]. Chest, 2012,141(4) : 1047-1054.
  • 9Rieci A, Mariotta S, Bronzetti E, et al. Serum CA 15-3 is increased in pulmonary fibrosis [J]. Sareoidosis Vase Diffuse Lung Dis, 2009,26( 1 ) : 54-63.
  • 10Kruit A, Gerritsen W B, Pot N, et al. CA 15-3 as an ahemative marker for KL-6 in fibrotie lung diseases [J]. Sarcoidosis Vase Diffuse Lung Dis, 2010,27(2):138-146.

共引文献35

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部